Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase

被引：0
|
作者：
Hongchuan Jin
Tobias Sperka
Peter Herrlich
Helen Morrison
机构：
[1] Leibniz Institute of Age Research–Fritz-Lipmann-Institute,Forschungszentrum Karlsruhe
[2] Institute of Toxicology and Genetics,Cancer Center, Department of Clinical Oncology, Prince of Wales Hospital
[3] The Chinese University of Hong Kong,undefined
来源：
Nature | 2006年 / 442卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The phosphatase that activates the Merlin tumour suppressor (also known as neurofibromatosis 2) has been identified. It's a myosin phosphatase that is inhibited by the endogenous inhibitor CPI-17, which is often upregulated in human tumours and may contribute to the development of cancer by inactivating Merlin. Taken together, these findings point to a novel cascade of tumour suppressors whose action can be abolished in at least two ways, by mutation (NF2) or upregulation of the putative novel oncogene, CPI-17.
引用
收藏
页码：576 / 579
页数：3
相关论文
共 50 条
  • [21] The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17
    Yoon, Hyuk-Jun
    Jung, Won Pill
    Min, Young Sil
    Jin, Fanxue
    Bang, Joon Seok
    Sohn, Uy Dong
    Je, Hyun Dong
    BIOMOLECULES & THERAPEUTICS, 2022, 30 (02) : 145 - 150
  • [22] CGMP signaling pathway regulates platelet shape change through modulation of myosin light chain phosphatase - the role of CPI-17 signalling
    Naseem, K. M.
    Aburima, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 399 - 400
  • [23] Dual Ser and Thr phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by MYPT-associated kinase
    MacDonald, JA
    Eto, M
    Borman, MA
    Brautigan, DL
    Haystead, TAJ
    FEBS LETTERS, 2001, 493 (2-3) : 91 - 94
  • [24] Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase
    Deng, JT
    Sutherland, C
    Brautigan, DL
    Eto, M
    Walsh, MP
    BIOCHEMICAL JOURNAL, 2002, 367 : 517 - 524
  • [25] Effect of Kaempferol on Modulation of Vascular Contractility Mainly through PKC and CPI-17 Inactivation
    Yoon, Hyuk-Jun
    Moon, Heui Woong
    Min, Young Sil
    Jin, Fanxue
    Bang, Joon Seok
    Sohn, Uy Dong
    Je, Hyun Dong
    BIOMOLECULES & THERAPEUTICS, 2024, 32 (03) : 361 - 367
  • [26] Glucocorticoids inhibited airway hyperresponsiveness through downregulation of CPI-17 in bronchial smooth muscle
    Goto, Kumiko
    Chiba, Yoshihiko
    Sakai, Hiroyasu
    Misawa, Miwa
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 591 (1-3) : 231 - 236
  • [27] Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits
    Eto, M
    Kitazawa, T
    Brautigan, DL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) : 8888 - 8893
  • [28] Localization of smooth muscle-specific type-1 protein phosphatase inhibitory protein (CPI-17).
    Li, S
    Eto, M
    Kitazawa, T
    BIOPHYSICAL JOURNAL, 1998, 74 (02) : A152 - A152
  • [29] Distinctive solution conformation of phosphatase inhibitor CPI-17 substituted with aspartate at the phosphorylation-site threohine residue
    Ohki, SY
    Eto, M
    Shimizu, M
    Takada, R
    Brautigan, DL
    Kainosho, M
    JOURNAL OF MOLECULAR BIOLOGY, 2003, 326 (05) : 1539 - 1547
  • [30] Role of CPI-17, an endogenous myosin phosphatase inhibitory protein, for gastrointestinal motility using genetically modified mice
    Hori, M.
    Maki, A.
    Yang, Q.
    Ozaki, H.
    Kaji, N.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30
12345